Drug Profile
Research programme: recombinant erythropoietin biosimilar - Biogenomics
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Biogenomics
- Class Antianaemics; Erythropoietins; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Anaemia in India (Parenteral, Injection)
- 16 Jan 2014 Research programme: recombinant erythropoietin biosimilar - Biogenomics is available for licensing in World as of 16 Jan 2014. http://www.biogenomics.co.in
- 16 Jan 2014 Early research in Anaemia in India (Parenteral)